REVIEWCoronavirus disease 2019 and the cardiologistMohammad, Khan O.a; Rodriguez, Jose B. Cruzb; Urey, Marcus A.b Author Information aDepartment of Internal Medicine, Dell Medical School at the University of Texas, Austin, Texas bDivision of Cardiovascular Medicine, Department of Medicine, University of California San Diego, San Diego, California, USA Correspondence to Jose B. Cruz Rodriguez, MD, MPH, 9452 Medical Center Drive #7411. La Jolla, CA 92037. Tel: +1 858 246 1326; fax: +1 858 657 1828; e-mail: [email protected] Current Opinion in Cardiology: July 12, 2022 - Volume - Issue - 10.1097/HCO.0000000000000958 doi: 10.1097/HCO.0000000000000958 Buy PAP Metrics Abstract Purpose of review There continues to be extensive clinical and epidemiological data to suggest that coronavirus disease 2019 (COVID-19) infection is associated with numerous different types of cardiac involvement. Recent findings Myocardial injury has been reported in over 25% of patients hospitalized due to COVID-19 infection and is not only associated with a worse prognosis but with higher mortality, approaching 40%. Currently proposed mechanisms of myocardial injury include direct viral infection, cytokine storm, endothelial inflammation, demand ischemia, interferon-mediated response and stress cardiomyopathy. COVID-19 infection is associated with new-onset arrhythmias and heart failure regardless of history of previous cardiovascular disease. Echocardiographic findings can be useful to predict mortality in COVID-19 patients and cardiac MRI is an effective tool to both assess COVID-19 induced myocarditis and to follow-up on cardiac complications of COVID-19 long-term. Although there is an association between COVID-19 vaccination and myocarditis, pericarditis or arrhythmias, the risk appears lower when compared to risk attributable to the natural infection. Summary Patients with cardiovascular disease are not only more likely to suffer from severe COVID-19 infection but are at increased risk for further complications and higher mortality. Further data compilation on current and emerging treatments of COVID-19 will have additional impact on cardiovascular morbidity and mortality of COVID-19 infection. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.